Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of medical device specialist Insulet surged 13% today after its quarterly results topped Wall Street expectations.
So what: Insulet's first-quarter loss narrowed to $10.67 million from $14.78 million in the year-ago period, reinforcing optimism over the company's newly introduced Omnipod insulin pump. In fact, revenue for the quarter surged 20% to $57.36 million on strong demand in both U.S. and international markets, giving Wall Street plenty of good vibes over Ominpod's adoption rate going forward.
Now what: Management still sees full-year 2013 revenue of $240 million-$255 million, bracketing Wall Street's view of $249.11 million.
"Demand for the new OmniPod has been tremendous with referrals and initial shipments up by more than 40% over the last two months as compared to the prior year," said President and CEO Duane DeSisto. "In the coming weeks, we expect to begin converting the existing customer base to the new OmniPod and continue to expect the transition to be completed by the end of the third quarter."
Of course, with the stock now up about 65% from its 52-week lows and trading at a price-to-sales multiple of 6, I'd wait for the some of the excitement to fade before buying into those prospects.
While you can certainly make huge gains in medical device specialists like Insulet, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.
Interested in more info on Insulet?Add it to your watchlist.
The article Why Insulet Shares Popped originally appeared on Fool.com.
Fool contributor Brian Pacampara has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.